Drug Profile


Alternative Names: VVP 808

Latest Information Update: 07 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Verva Pharmaceuticals
  • Class Antiglaucomas; Antihyperglycaemics; Small molecules; Thiadiazoles
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 20 Jul 2015 Phase II development is ongoing in Australia
  • 20 Jul 2015 An undisclosed US Biotechnology company acquires methazolamide from Verva Pharmaceuticals
  • 01 Dec 2009 Phase-II clinical trials in Type-2 diabetes mellitus in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top